Close Menu

NEW YORK (GenomeWeb) – CanHelp, a recently formed Chinese diagnostics company, is pushing forward with plans to commercialize a variety of gene expression tests for the subtyping or differentiation of various cancers.

The company said in an email today that it has validated three PCR-based tests — one for cancers of unknown primary (CUP), one for lung cancer, and one for renal cancer — and is now in the process of seeking China Food and Drug Administration approval for them. The firm also has plans for at least two other assays in the works.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.